Abbott Laboratories (NYSE:ABT) Releases Earnings Results, Beats Estimates By $0.01 EPS

Abbott Laboratories (NYSE:ABT) posted its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01, MarketWatch Earnings reports. The firm had revenue of $6.83 billion during the quarter, compared to analysts’ expectations of $6.72 billion. Abbott Laboratories had a return on equity of 14.50% and a net margin of 8.37%. The firm’s quarterly revenue was up 28.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.59 EPS. Abbott Laboratories updated its Q4 guidance to $0.72-0.74 EPS.

Shares of Abbott Laboratories (NYSE ABT) opened at 55.52 on Friday. The stock has a 50 day moving average price of $53.58 and a 200 day moving average price of $48.80. The firm has a market cap of $96.46 billion, a price-to-earnings ratio of 77.76 and a beta of 1.06. Abbott Laboratories has a one year low of $37.38 and a one year high of $56.69.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be given a dividend of $0.265 per share. The ex-dividend date is Thursday, October 12th. This represents a $1.06 dividend on an annualized basis and a yield of 1.91%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 83.47%.

In other news, insider Daniel Gesua Sive Salvadori sold 62,460 shares of the stock in a transaction dated Tuesday, September 26th. The shares were sold at an average price of $52.95, for a total transaction of $3,307,257.00. Following the transaction, the insider now owns 113,426 shares of the company’s stock, valued at approximately $6,005,906.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jaime Contreras sold 52,700 shares of the stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $51.97, for a total transaction of $2,738,819.00. Following the transaction, the insider now directly owns 58,739 shares in the company, valued at approximately $3,052,665.83. The disclosure for this sale can be found here. Insiders have sold 410,313 shares of company stock worth $21,303,676 in the last ninety days. Insiders own 0.76% of the company’s stock.

Large investors have recently bought and sold shares of the business. Albion Financial Group UT purchased a new stake in shares of Abbott Laboratories during the 2nd quarter worth approximately $211,000. Ackerman Capital Advisors LLC purchased a new stake in shares of Abbott Laboratories during the 2nd quarter worth approximately $231,000. TLP Group LLC purchased a new stake in shares of Abbott Laboratories during the 2nd quarter worth approximately $254,000. Coldstream Capital Management Inc. increased its stake in shares of Abbott Laboratories by 9.7% during the 2nd quarter. Coldstream Capital Management Inc. now owns 5,484 shares of the healthcare product maker’s stock worth $267,000 after purchasing an additional 485 shares during the last quarter. Finally, Segment Wealth Management LLC purchased a new stake in shares of Abbott Laboratories during the 2nd quarter worth approximately $268,000. Hedge funds and other institutional investors own 71.42% of the company’s stock.

ABT has been the topic of several research analyst reports. TheStreet raised Abbott Laboratories from a “c+” rating to a “b” rating in a research note on Monday, July 3rd. BidaskClub lowered Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Jefferies Group LLC reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Abbott Laboratories in a research note on Thursday, August 3rd. Guggenheim began coverage on Abbott Laboratories in a research note on Thursday, June 29th. They issued a “buy” rating and a $58.00 price objective on the stock. Finally, Stifel Nicolaus reissued a “buy” rating and set a $58.00 price target on shares of Abbott Laboratories in a research report on Friday, July 21st. Seven investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $56.81.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/27/abbott-laboratories-abt-issues-earnings-results.html.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Earnings History for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply